EDMUND C. LIPP JR., M.D.; RICHARD A. RUDDERS, M.D.; ANTHONY V. PISCIOTTA, M.D.
Oral urea was administered to five patients with homozygous sickle-cell anemia who were not in crisis, to study its effect on chronic hemolysis. After a suitable control period the subjects were given urea orally (1 g/kg body weight · day) for 3½ to 7 weeks. At the end of the study period there was no significant change in the level of anemia nor degree of hemolysis in each subject. One patient developed a painful crisis while receiving urea. The only statistically significant group change noted was elevation of the blood urea nitrogen. In three patients there may have been increased hemolysis during therapy, reflected by increased fecal urobilinogen excretion. In these five patients there was no apparent clinical benefit from oral urea administration.
LIPP EC, RUDDERS RA, PISCIOTTA AV. Oral Urea Therapy in Sickle-Cell Anemia: A Preliminary Report. Ann Intern Med. ;76:765–768. doi: 10.7326/0003-4819-76-5-765
Download citation file:
Published: Ann Intern Med. 1972;76(5):765-768.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use